Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1793-1796

  Bélanger, Anne Sophie ^a   Caron, Patrick ^a   Harvey, Mario ^a   Zimmerman, Peter A ^b   Mehlotra, Rajeev K ^b   Guillemette, Chantal ^a  

^a Université Laval   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; DRUG CONJUGATION; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INDICATORS AND REAGENTS; KINETICS; MICROSOMES, LIVER; REVERSE TRANSCRIPTASE INHIBITORS; TANDEM MASS SPECTROMETRY; ZIDOVUDINE;

EID: 70349108450     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027706     Document Type: Article

References (23)

1. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, and Csajka C (2009) Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85:485-494.
2. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Bélanger A (2000) 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502. (Pubitemid 30238507)
3. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77. (Pubitemid 28071328)
4. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, et al. (2009) In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19:300-309.
5. Duguay Y, Báár C, Skorpen F, and Guillemette C (2004) A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223-233. (Pubitemid 38314872)
6. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
7. Herber R, Magdalou J, Haumont M, Bidault R, van Es H, and Siest G (1992) Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim Biophys Acta 1139:20-24.
8. Hoetelmans RM (1999) Pharmacology of antiretroviral drugs. Antivir Ther 4 (Suppl 3):29-41.
9. Innocenti F, Iyer L, Ramírez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692. (Pubitemid 32374570)
10. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412. (Pubitemid 28477680)
11. Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, and Agrawal KC (1994) Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 56:272-278. (Pubitemid 24323918)
12. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. (Pubitemid 32055781)
13. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, and Christ DD (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319-1333.
14. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, and Maartens G (2008) Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 22:2117-2125.
15. Resetar A, Minick D, and Spector T (1991) Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol 42:559-568.
16. Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, and Soriano V (2006) Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 6:234-245.
17. Rodriguez-Novoa S, Barreiro P, Rendón A, Jiménez-Nacher I, González-Lahoz J, and Soriano V (2005) Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 40:1358-1361. (Pubitemid 40570249)
18. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
19. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080. (Pubitemid 32900389)
20. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.
21. Villeneuve L, Girard H, Fortier LC, Gagné JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128. (Pubitemid 37151897)
22. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
23. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)